Selank and Semax Named as Underdiscussed Anxiety and Stress Peptides in Gemelli-Greenfield Discussion
In a podcast on peptide channel takedowns, Dylan Gemelli names Selank and Semax as two peptides he considers underdiscussed, framing them as options for anxiety and stress and citing a family history of anxiety plus dissatisfaction with conventional anxiolytic treatment. He predicts attention will move past GLP-1s toward peptides targeting the mind, heart, liver and kidneys. No dosing, route, cycling, or outcome data is provided, and the speakers state the compounds are discussed for research purposes only. This is opinion and market commentary, not clinical evidence.
Prescription Requirement: Medical Oversight Recommended for Peptide Selection
The speaker concludes by directing viewers to seek a medical team for proper prescription and individualized selection between Selank and Semax. This implies the compounds require or benefit from professional oversight rather than self-directed use. No safety contraindications are explicitly detailed.
Route of Administration: Both Peptides Available as Nasal Spray
The speaker references nasal spray as the delivery format for both Selank and Semax, implying intranasal administration is the standard or preferred route discussed in this context. No specific dosage, concentration, or spray frequency is mentioned.
Pre-Optimization Protocol: Address Sleep and Inflammation Before Peptide Use
The speaker recommends resolving sleep issues and systemic inflammation as foundational steps before introducing either Selank or Semax. This is framed as a prerequisite to ensure the peptides function as precision tools rather than expensive guesses. No specific sleep or inflammation protocols are detailed.
Stacking Selank and Semax Together: Cautionary Recommendation Against Default Stacking
The speaker explicitly cautions against stacking both Selank and Semax by default, stating that doing so may result in paying for a signal the user does not need. The recommendation is to identify the specific cognitive gap first and use only the peptide that addresses it. No dosage information is provided.
Selank vs. Semax: Symptom-Matched Selection Protocol
The speaker argues that Selank and Semax address opposite cognitive bottlenecks — low arousal/fog versus high arousal/anxiety — and that users should select only the compound matching their specific problem. The framing is that the two peptides are not interchangeable or redundant, and choosing incorrectly wastes money on an unneeded signal.
Semax Mechanism: BDNF Upregulation for Focus and Cognitive Drive
Semax is described as pushing Brain-Derived Neurotrophic Factor (BDNF), characterized as 'fertilizer for neurons.' This mechanism is said to sharpen focus, recall, and drive. It is positioned as the appropriate tool when the user experiences mental flatness or brain fog.
We Just Won the Biggest Peptide Battle Yet
Dihexa and Semax were scheduled for day two of the FDA Pharmacy Compounding Advisory Committee meeting. Dr Alex reports from the meeting that the committee recommended moving BPC-157, TB-500, KPV and MOTS-c to the 503A bulk list, which if formally accepted could restore compounded prescription access by the end of 2026. He states the remaining three compounds - epitalon, dihexa and Semax (rendered 'C-max' in the auto transcript) - were on the agenda for the following day, so their outcome is not yet decided in this video. The FDA livestreamed the session. This is advocacy and regulatory reporting from the American Academy for Peptide Medicine side, not clinical evidence on Dihexa or Semax, and the day two result still needs confirmation.
It is Official: 7 Life-Changing Peptides are BACK.
Overview of the FDA/PCAC peptide landscape. Describes Semax (as C-Max) as a stroke-recovery/cognitive agent, Selank as a non-sedating anxiolytic, and Dihexa as a potent synaptogenic compound (technically not a peptide). Context on the 2023 gray-market shift and PCAC scheduling.
Semax: The Ultimate Guide to Cognitive Enhancement and Neuroprotection
Clinician-oriented Semax guide. Indications: cognitive/memory enhancement, anxiety/depression, ischemic stroke and brain-injury recovery, ADHD, neuroprotection, optic nerve disorders, chronic fatigue, pain. Mechanisms: raised BDNF, dopaminergic/serotonergic modulation, improved cerebral blood flow, antioxidant effects, melanocortin receptor binding. Dosing: nasal 300-1000mcg/day (up to 3000), SC 100-500mcg/day (up to 1000), 10-14 day cycles. Caution in bipolar disorder, avoid in pregnancy. Expert clinical explanation.
The Limitless Peptide Actually Exists...
Long-form Semax deep dive framing the Russian heptapeptide nasal spray as a real-world nootropic for cognitive enhancement and neuroprotection against stroke damage; reviews largely Russian-language literature. Creator opinion, not primary evidence.
How does the Peptide Semax Work?
Explainer on Semax mechanism: a 7-amino-acid ACTH(4-10) analog that raises BDNF to strengthen synapses, improving learning, memory and cognition; noted use in stroke and brain-injury research. Educational/creator opinion.
Hypothetical Framing of Peptide Dosages as Legal Disclaimer
The speaker repeatedly uses the qualifier 'hypothetically' when stating peptide dosages (SS-31 at 2 mg/day, MOTS-c at 1 mg/day, Semax at 400 mcg/day), framing the recommendations as hypothetical for a 'kangaroo' rather than direct human prescriptions. This appears to be a legal disclaimer strategy. The dosages are nonetheless presented with specificity and clinical intent within the context of a burnout recovery protocol. [Audit 2026-10-04: 'Cax' was a caption mangling of Semax.]
Semax Dopaminergic Recovery Timeline: Expected Response at Two Weeks
The speaker provides a specific expected timeline for Semax's effect on dopaminergic system recovery, stating that the 'choice gap' — the ability to pause between stimulus and response indicating restored prefrontal cortex and dopamine function — should return within approximately two weeks on the protocol. If the patient is still reactive and running on fumes at two weeks, the speaker suggests the protocol needs tweaking. This is framed as a subjective but clinically meaningful biomarker of neurochemical recovery. [Audit 2026-10-04: 'Cax' was a caption mangling of Semax.]
Peptide Stack Overloading Warning: Metabolic Chaos from Excessive Compound Stacking
The speaker issues a direct warning against stacking too many compounds simultaneously, including peptides, citing the example of patients taking 14+ supplements including 'a whole bunch of peptides.' He argues this creates metabolic chaos, overloads the liver and kidneys, and adds additional processing burden to already-failing mitochondria. The warning is framed as a safety and efficacy concern: more compounds do not equal more optimization and can actively worsen the underlying mitochondrial failure being treated.
Full Burnout Recovery Stack: SS-31, MOTS-c, NAD+, CoQ10, PQQ, L-Tyrosine, Semax, Magnesium Bisglycinate, L-Theanine
The speaker presents a comprehensive multi-compound protocol targeting each biochemical mechanism of burnout: SS-31 (2 mg/day) and MOTS-c (1 mg/day) for mitochondrial repair; NAD+ (50 mg/day) for electron transport and DNA repair enzyme activation; CoQ10 (200 mg/day) and PQQ (20 mg/day) for electron carrier substrate and biogenesis signaling; L-Tyrosine (3 g/day) as dopamine/norepinephrine precursor; Semax (400 mcg/day morning) for BDNF-mediated dopaminergic recovery; Magnesium Bisglycinate (500 mg before bed) as NMDA antagonist; and L-Theanine (200 mg before bed) for GABA promotion and glutamate excitotoxicity reduction. The speaker states this protocol takes 20–30 days. [Audit 2026-10-04: 'Cax' was a caption mangling of Semax.]
Semax Distinguished from Stimulants: Mechanism of Action Safety Clarification
The speaker makes a specific safety and mechanistic distinction that 'Semax' does not act as a dopamine releaser or amphetamine-like stimulant, contrasting it with Adderall, Ritalin, and energy drinks that force dopamine output and deplete reserves. This is framed as a critical differentiator for burned-out patients whose dopamine synthesis enzymes and BH4 cofactors are already depleted. Using a stimulant in this state worsens the underlying biochemical deficit, whereas Semax works through a restorative BDNF pathway. [Audit 2026-10-04: 'Cax' was a caption mangling of Semax.]
Semax for Dopaminergic System Recovery via BDNF
The speaker recommends a compound referred to as 'Semax,' clarifying it is not a dopamine releaser or amphetamine and does not force output. It is described as working through BDNF (Brain-Derived Neurotrophic Factor) signaling to grow new neuronal connections and recover the dopaminergic system. A dosage of 400 micrograms every day in the morning is specified. The speaker emphasizes it restores dopamine system integrity without forcing depletion of existing stores. [Audit 2026-10-04: 'Cax' was a caption mangling of Semax.]